130 related articles for article (PubMed ID: 38299430)
1. Quality use of publicly subsidised tapentadol in Australia: a population-based analysis.
Camacho X; Schaffer AL; Brett J; Pratt N; Buckley NA; Henry D; Pearson SA
Intern Med J; 2024 Jun; 54(6):941-950. PubMed ID: 38299430
[TBL] [Abstract][Full Text] [Related]
2. The impact of tightened prescribing restrictions for PBS-subsidised opioid medicines and the introduction of half-pack sizes, Australia, 2020-21: an interrupted time series analysis.
Koch FC; Olivier J; Brett J; Buckley NA; Gisev N; Pearson S; Daniels B
Med J Aust; 2024 Apr; 220(6):315-322. PubMed ID: 38522006
[TBL] [Abstract][Full Text] [Related]
3. Trends in opioid utilisation in Australia, 2006-2015: Insights from multiple metrics.
Karanges EA; Buckley NA; Brett J; Blanch B; Litchfield M; Degenhardt L; Pearson SA
Pharmacoepidemiol Drug Saf; 2018 May; 27(5):504-512. PubMed ID: 29280224
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness and tolerability of tapentadol prolonged release compared with prior opioid therapy for the management of severe, chronic osteoarthritis pain.
Steigerwald I; Schenk M; Lahne U; Gebuhr P; Falke D; Hoggart B
Clin Drug Investig; 2013 Sep; 33(9):607-19. PubMed ID: 23912473
[TBL] [Abstract][Full Text] [Related]
5. Opioid use and harms associated with a sustained-release tapentadol formulation: a postmarketing study protocol.
Peacock A; Larance B; Farrell M; Cairns R; Buckley N; Degenhardt L
BMJ Open; 2018 Mar; 8(3):e020006. PubMed ID: 29574444
[TBL] [Abstract][Full Text] [Related]
6. Ready conversion of patients with well-controlled, moderate to severe, chronic malignant tumor-related pain on other opioids to tapentadol extended release.
Imanaka K; Tominaga Y; Etropolski M; Ohashi H; Hirose K; Matsumura T
Clin Drug Investig; 2014 Jul; 34(7):501-11. PubMed ID: 24906437
[TBL] [Abstract][Full Text] [Related]
7. Twenty-five years of prescription opioid use in Australia: a whole-of-population analysis using pharmaceutical claims.
Karanges EA; Blanch B; Buckley NA; Pearson SA
Br J Clin Pharmacol; 2016 Jul; 82(1):255-67. PubMed ID: 26991673
[TBL] [Abstract][Full Text] [Related]
8. Opioid analgesic prescribing in Australia: a focus on gender and age.
Hollingworth SA; Gray PD; Hall WD; Najman JM
Pharmacoepidemiol Drug Saf; 2015 Jun; 24(6):628-36. PubMed ID: 25845470
[TBL] [Abstract][Full Text] [Related]
9. Opioid use and harms associated with a sustained-release tapentadol formulation: A post-marketing surveillance study.
Peacock A; Gisev N; Memedovic S; Larance B; Brown J; Cairns R; Buckley N; Farrell M; Degenhardt L
Drug Alcohol Depend; 2020 Jan; 206():107697. PubMed ID: 31869601
[TBL] [Abstract][Full Text] [Related]
10. The impact of tightened prescribing restrictions on proton pump inhibitor use in Australia: An evaluation using interrupted time series analysis.
Daniels B; Schaffer A; Buckley NA; Bruno C; Jun M; Pearson SA; Zoega H
Pharmacoepidemiol Drug Saf; 2022 Mar; 31(3):370-378. PubMed ID: 34894368
[TBL] [Abstract][Full Text] [Related]
11. Anticipating the effects of restricting high-dose preparations of strong opioids in Australia: A population-based analysis to inform the current policy debate.
Zheng D; Narayan SW; Zoega H; Litchfield M; Buckley NA; Pearson SA; Schaffer AL
Pharmacoepidemiol Drug Saf; 2019 Apr; 28(4):521-527. PubMed ID: 30790376
[TBL] [Abstract][Full Text] [Related]
12. Cohort protocol paper: the Pain and Opioids In Treatment (POINT) study.
Campbell G; Mattick R; Bruno R; Larance B; Nielsen S; Cohen M; Lintzeris N; Shand F; Hall WD; Hoban B; Kehler C; Farrell M; Degenhardt L
BMC Pharmacol Toxicol; 2014 Mar; 15():17. PubMed ID: 24646721
[TBL] [Abstract][Full Text] [Related]
13. Prescription opioid dispensing in Australian children and adolescents: a national population-based study.
Bell J; Paget SP; Nielsen TC; Buckley NA; Collins J; Pearson SA; Nassar N
Lancet Child Adolesc Health; 2019 Dec; 3(12):881-888. PubMed ID: 31604614
[TBL] [Abstract][Full Text] [Related]
14. Increases in controlled-release oxycodone utilisation following the subsidy of oxycodone with naloxone formulations: An Australian population-based study.
Schaffer AL; Karanges EA; Buckley NA; Wilson A; Degenhardt L; Larance B; Pearson SA
Pharmacoepidemiol Drug Saf; 2019 Jan; 28(1):97-105. PubMed ID: 30421838
[TBL] [Abstract][Full Text] [Related]
15. Characterising the use of varenicline: an analysis of the Australian dispensing claims data.
Gobarani RK; Ilomäki J; Wood S; Abramson MJ; Bonevski B; George J
Addiction; 2022 Oct; 117(10):2683-2694. PubMed ID: 35603915
[TBL] [Abstract][Full Text] [Related]
16. Health service utilisation by people living with chronic non-cancer pain: findings from the Pain and Opioids IN Treatment (POINT) study.
Nielsen S; Campbell G; Peacock A; Smith K; Bruno R; Hall W; Cohen M; Degenhardt L
Aust Health Rev; 2016 Nov; 40(5):490-499. PubMed ID: 26599263
[TBL] [Abstract][Full Text] [Related]
17. A comparison of opioids and benzodiazepines dispensing in Australia.
Islam MM; Wollersheim D
PLoS One; 2019; 14(8):e0221438. PubMed ID: 31425552
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness and tolerability of tapentadol sustained release in the Australian setting.
Russo MA; Santarelli DM
J Opioid Manag; 2016; 12(3):187-96. PubMed ID: 27435439
[TBL] [Abstract][Full Text] [Related]
19. Prevalence and incidence of prescription opioid analgesic use in Australia.
Lalic S; Ilomäki J; Bell JS; Korhonen MJ; Gisev N
Br J Clin Pharmacol; 2019 Jan; 85(1):202-215. PubMed ID: 30338545
[TBL] [Abstract][Full Text] [Related]
20. Tapentadol Prolonged Release for Severe Chronic Osteoarthritis Pain in the Elderly-A Subgroup Analysis of Routine Clinical Practice Data.
Schwittay A; Sohns M; Heckes B; Elling C
Pain Res Manag; 2020; 2020():5759265. PubMed ID: 32351639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
